In a woman with female pattern hair loss and a first-degree relative with breast cancer, what is the risk of breast cancer associated with using 5‑alpha‑reductase inhibitors such as finasteride or dutasteride?

5-Alpha Reductase Inhibitors and Breast Cancer Risk in Women with Family History

There is no evidence that 5-alpha reductase inhibitors (finasteride or dutasteride) increase breast cancer risk in women, including those with a first-degree relative with breast cancer, and these medications can be safely used for female pattern hair loss in this population.

Evidence Base

The concern about 5-ARIs and breast cancer stems primarily from male studies and theoretical hormonal considerations, but the actual data in women is reassuring:

Direct Evidence in Women

The most comprehensive safety review specifically addressing this question found that 5-ARIs do not increase breast cancer risk in women 1. This 2019 systematic review examined sex hormone alterations in 284 female patients on 5-ARIs and found:

• Estrogen levels increased in only 34% of patients
• Estrogen levels remained unchanged in 57% of patients
• Estrogen levels actually decreased in 5.3% of patients
• No studies reported increased breast cancer risk with 5-ARI use in women

A 2025 comprehensive safety review reinforced that 5-ARIs can be used in breast cancer patients and high-risk women, noting the importance of understanding safe treatment options given that 1 in 8 women will develop breast cancer 2.

Male Data (Not Applicable But Reassuring)

Studies in men consistently show no increased breast cancer risk with 5-ARI use:

• A 2018 meta-analysis of 595,776 male participants found no association between 5-ARIs and breast cancer (RR 1.16,95% CI 0.85-1.58, p=0.36) 3
• A 2014 UK study of 398 male breast cancer cases found no increased risk with 5-ARI use (OR 1.08,95% CI 0.62-1.87) 4
• A 2017 cohort study confirmed no increased breast cancer risk in 5-ARI users (OR 1.52,95% CI 0.61-3.80) 5

FDA Labeling Considerations

Critical caveat: Both finasteride and dutasteride are absolutely contraindicated in pregnancy due to teratogenic effects on male fetuses 6, 7. Women of childbearing potential must use reliable contraception.

The FDA labels for these medications focus on:

• Male prostate cancer concerns (not relevant to female breast cancer)
• Pregnancy contraindication (relevant for all women of childbearing age)
• No mention of female breast cancer risk

Clinical Application for Your Patient

For a woman with female pattern hair loss and a first-degree relative with breast cancer:

You can safely prescribe 5-ARIs with the following considerations:

1. Ensure she is postmenopausal or using reliable contraception (pregnancy Category X)

2. Family history of breast cancer is NOT a contraindication - the evidence shows no increased breast cancer risk with 5-ARI use

3. Consider starting with finasteride rather than dutasteride:

   • Finasteride has more clinical data in women 8
   • Dutasteride showed higher gynecomastia risk in men (though this doesn't translate to female breast cancer risk) 5

4. Topical formulations may be preferred to minimize systemic absorption, though efficacy data is more limited 8

5. Monitor as you would any high-risk patient - the 5-ARI itself doesn't add breast cancer risk, but her family history warrants standard breast cancer screening per guidelines 9

Important Distinction

The ASCO breast cancer risk reduction guideline discusses endocrine therapy (tamoxifen, aromatase inhibitors) for women at high risk 9, but this is completely separate from the question of whether 5-ARIs cause breast cancer. The guideline does not list 5-ARIs as contraindicated in high-risk women.

Bottom line: Having a first-degree relative with breast cancer does not preclude using 5-ARIs for female pattern hair loss. The evidence consistently shows no increased breast cancer risk with these medications in women.